Advanced therapies for PAH hold promise in adults with CHD-related PAH, but supportive care and addressing other causes of functional limitation remain crucial given the unique pathophysiology.
No takes yet. Share an insight, caveat, or question.
Supports cautious integration of advanced PAH therapies with supportive care in CHD adults; leaves open dedicated RCTs given unique pathophysiology.
Dimopoulos et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: